Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RGS12 | O14924 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL140158 | 0.80 | EGFR (0.50) | DNM1MAPTEGFRERBB2CYP1A2 | |
| SCHEMBL108595 | 0.80 | EGFR (0.50) | DNM1MAPTEGFRERBB2CYP1A2 | |
| SCHEMBL140953 | 0.80 | EGFR (0.50) | DNM1MAPTEGFRERBB2CYP1A2 | |
| SCHEMBL5500195 | 0.78 | HDAC6 (0.49) | DNM1AKR1B10TTRAKR1B1APP | |
| SCHEMBL5500196 | 0.78 | HDAC6 (0.49) | DNM1AKR1B10TTRAKR1B1APP | |
| SCHEMBL22263055 | 0.68 | MEN1 (0.49) | LMNAKDM4EMEN1POLBKMT2A | |
| SCHEMBL27828053 | 0.67 | HDAC6 (0.72) | MAPTRECQLKDM4EPOLBL3MBTL1 | |
| SCHEMBL10716827 | 0.65 | MEN1 (0.53) | AKR1B10TTRAKR1B1LMNAMEN1 | |
| SCHEMBL18904517 | 0.65 | KDM4E (0.45) | TTRAPPMAPTEGFRCYP1A2 | |
| SCHEMBL27417592 | 0.65 | KDM4E (0.44) | AKR1B1APPMAPTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227643-B2 | Sirtuin 1 and the treatment of neurodegenerative diseases | PROTEOTECH, INC. (US) | 2012-07-24 | — | — | US | claimed |
| US-20120058998-A1 | Compounds, Compositions and Methods for the Treatment of Inflammatory Diseases | PROTAMED, INC. | 2012-03-08 | — | — | US | claimed |
| US-20110015272-A1 | Sirtuin 1 and the Treatment of Neurodegenerative Diseases | PROTEOTECH INC. | 2011-01-20 | — | — | US | claimed |
| US-7714170-B2 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTEOTECH, INC. (US) | 2010-05-11 | — | — | US | claimed |
| US-7601876-B2 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTEOTECH, INC. (US) | 2009-10-13 | — | — | US | claimed |
| US-20090143374-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTAMED, INC. | 2009-06-04 | — | — | US | claimed |
| WO-2009017848-A9 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES SUCH AS SYSTEMIC AA AMYLOIDOSIS | PROTEO TECH INC (US) | 2009-04-30 | — | — | WO | claimed |
| WO-2009017848-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES SUCH AS SYSTEMIC AA AMYLOIDOSIS | PROTEO TECH INC. (US) | 2009-02-05 | — | — | WO | claimed |
| WO-2008154083-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | PROTEO TECH INC. (US) | 2008-12-18 | — | — | WO | claimed |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | claimed |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTAMED, INC. | 2007-09-27 | — | — | US | claimed |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH INC. | 2007-09-06 | — | — | US | claimed |
| EP-1751097-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | Proteotech, Inc. (US) | 2007-02-14 | — | — | EP | claimed |
| US-20060199838-A1 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | PROTAMED, INC. | 2006-09-07 | — | — | US | claimed |
| WO-2005113489-A1 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTEOTECH, INC. (US) | 2005-12-01 | — | — | WO | claimed |
| US-20040127555-A1 | bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis | PROTAMED, INC. | 2004-07-01 | — | — | US | claimed |
| US-20170008838-A1 | COMPOUNDS AND COMPOSITIONS FOR USE AS MODULATORS OF TAU AGGREGATION AND ALLEVIATION OF TAUOPATHIES | PROTAMED INC (US) | 2017-01-12 | — | — | US | disclosed |
| US-9469605-B2 | Compounds and compositions for use a modulators of tau aggregation and alleviation of tauopathies | PROTAMED, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20060199838-A1 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | PROTAMED, INC. | 2006-09-07 | — | — | US | disclosed |
| US-20040127555-A1 | bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis | PROTAMED, INC. | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127555-A1 | bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis | IAPP, SNCA, IDE | DNM1 662/4885AKR1B10 2984/4885TTR 7/4885 |
| US-20060199838-A1 | Substituted N-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies | IAPP, SNCA, BACE2 | DNM1 2433/4885AKR1B10 2027/4885TTR 51/4885 |
| US-20120058998-A1 | Compounds, Compositions and Methods for the Treatment of Inflammatory Diseases | NR1H2, NR1H3, MSR1 | DNM1 1490/4885AKR1B10 137/4885TTR 1041/4885 |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | NR1H2, NR1H3, NR1H4 | DNM1 2654/4885AKR1B10 185/4885TTR 1806/4885 |
| US-20170008838-A1 | COMPOUNDS AND COMPOSITIONS FOR USE AS MODULATORS OF TAU AGGREGATION AND ALLEVIATION OF TAUOPATHIES | PSEN2, PSEN1, MAPT | DNM1 1986/4885AKR1B10 4540/4885TTR 805/4885 |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | IAPP, SNCA, APP | DNM1 2671/4885AKR1B10 901/4885TTR 4/4885 |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | SNCA, PARK7, COMT | DNM1 287/4885AKR1B10 3118/4885TTR 52/4885 |
| US-20090143374-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | APP, BACE1, BACE2 | DNM1 1106/4885AKR1B10 955/4885TTR 13/4885 |
| US-20110015272-A1 | Sirtuin 1 and the Treatment of Neurodegenerative Diseases | SIRT1, SIRT3, SIRT2 | DNM1 258/4885AKR1B10 2611/4885TTR 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.